Free Trial

Phio Pharmaceuticals (PHIO) Competitors

Phio Pharmaceuticals logo
$2.11 -0.01 (-0.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 -0.01 (-0.47%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PHIO vs. ATNM, AADI, INMB, IPSC, ADAP, VNRX, ESLA, KPTI, LTRN, and MRSN

Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), INmune Bio (INMB), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), VolitionRx (VNRX), Estrella Immunopharma (ESLA), Karyopharm Therapeutics (KPTI), Lantern Pharma (LTRN), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry.

Phio Pharmaceuticals vs. Its Competitors

Actinium Pharmaceuticals (NYSE:ATNM) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Actinium Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

In the previous week, Actinium Pharmaceuticals had 4 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for Actinium Pharmaceuticals and 0 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.95 beat Actinium Pharmaceuticals' score of -0.33 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Actinium Pharmaceuticals Neutral
Phio Pharmaceuticals Positive

Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 208.22%. Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 563.51%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Phio Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.11
Phio PharmaceuticalsN/AN/A-$7.15M-$3.25-0.65

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals' return on equity of -88.75% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Phio Pharmaceuticals N/A -88.75%-77.98%

Summary

Phio Pharmaceuticals beats Actinium Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHIO vs. The Competition

MetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.09M$2.63B$6.09B$10.54B
Dividend YieldN/A57.78%5.73%4.78%
P/E Ratio-0.6522.9984.6327.10
Price / SalesN/A761.84606.05131.34
Price / CashN/A175.9337.8662.13
Price / Book3.065.3212.246.58
Net Income-$7.15M$33.06M$3.32B$276.75M
7 Day Performance-4.09%-0.81%0.76%0.91%
1 Month PerformanceN/A9.20%8.03%4.18%
1 Year Performance-20.38%-3.82%71.13%35.42%

Phio Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHIO
Phio Pharmaceuticals
1.9976 of 5 stars
$2.11
-0.5%
$14.00
+563.5%
-34.8%$12.09MN/A-0.6510
ATNM
Actinium Pharmaceuticals
2.1922 of 5 stars
$1.61
+8.1%
$4.50
+179.5%
-13.1%$50.23MN/A-1.1630
AADI
Aadi Bioscience
N/A$2.02
-6.9%
N/A-1.9%$49.89M$25.07M-0.8940Gap Up
INMB
INmune Bio
2.1425 of 5 stars
$1.83
-1.6%
$18.50
+910.9%
-64.5%$49.45M$10K-0.7410
IPSC
Century Therapeutics
2.7822 of 5 stars
$0.55
-3.3%
$3.75
+581.9%
-64.5%$49.13M$6.59M-1.90170
ADAP
Adaptimmune Therapeutics
1.9705 of 5 stars
$0.18
-2.6%
$1.35
+650.5%
-77.6%$49.01M$178.03M-0.28490Gap Down
VNRX
VolitionRx
2.5983 of 5 stars
$0.45
-2.5%
$3.50
+673.1%
-39.1%$48.71M$1.32M-1.2680News Coverage
Gap Up
High Trading Volume
ESLA
Estrella Immunopharma
2.6753 of 5 stars
$1.50
+16.3%
$16.00
+966.7%
+87.3%$47.81MN/A-5.77N/AShort Interest ↓
Gap Down
High Trading Volume
KPTI
Karyopharm Therapeutics
4.1999 of 5 stars
$5.62
+2.2%
$18.20
+223.8%
-52.6%$47.69M$145.24M-0.39380Analyst Revision
LTRN
Lantern Pharma
1.9179 of 5 stars
$4.41
+1.6%
$25.00
+466.9%
+23.4%$46.87MN/A-2.4820News Coverage
Gap Down
MRSN
Mersana Therapeutics
4.3022 of 5 stars
$9.91
+7.3%
$56.60
+471.1%
-80.0%$46.11M$40.50M-0.68150High Trading Volume

Related Companies and Tools


This page (NASDAQ:PHIO) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners